Forsidebilde av showet JAMA Clinical Reviews

JAMA Clinical Reviews

Podkast av JAMA Network

engelsk

Teknologi og vitenskap

Prøv gratis i 14 dager

99 kr / Måned etter prøveperioden.Avslutt når som helst.

  • 20 timer lydbøker i måneden
  • Eksklusive podkaster
  • Gratis podkaster
Prøv gratis

Les mer JAMA Clinical Reviews

Author interviews that explore the latest clinical reviews.

Alle episoder

489 Episoder

episode Point-of-Care Ultrasound for the Diagnosis of Pneumonia: A Review cover

Point-of-Care Ultrasound for the Diagnosis of Pneumonia: A Review

Community-acquired pneumonia (CAP) accounts for 1.4 million emergency department visits and 740 000 hospitalizations annually in the US. Author Andre Kumar, MD, MEd, of Stanford University School of Medicine joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the use of point-of-care ultrasound for diagnosis of CAP. Related Content: * Point-of-Care Ultrasound for the Diagnosis of Pneumonia [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4782?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Bedside Lung Ultrasound in Emergency (BLUE) for Evaluation of Dyspnea [https://edhub.ama-assn.org/jn-learning/video-player/10.1001/jama.2026.6399?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

3. juni 2026 - 16 min
episode Cesarean Delivery on Request cover

Cesarean Delivery on Request

Cesarean delivery on maternal request requires individualized counseling. Reduced risks of pelvic floor disorders should be weighed against surgical risks and future risks including abnormal placentation. Author Marianna Alperin, MD, MS, from UC San Diego School of Medicine, discusses this and more with JAMA Deputy Editor Linda Brubaker, MD. Related Content: * Cesarean Delivery on Maternal Request [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.26633?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Cesarean Delivery—Reply [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6781?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Cesarean Delivery [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6779?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

27. mai 2026 - 15 min
episode Diet and Exercise Recommendations for Patients Taking GLP-1 Receptor Agonists cover

Diet and Exercise Recommendations for Patients Taking GLP-1 Receptor Agonists

The GLP-1 receptor agonists reduce appetite and greatly facilitate weight loss. Robert Kushner, MD, of Northwestern University Feinberg School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss appropriate diet and exercise recommendations for patients receiving GLP-1 receptor agonists for weight loss. Related Content: * Lifestyle Modification and Incretin-Based Therapy for Obesity [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4106?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5537?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

20. mai 2026 - 14 min
episode An Overview of Amyotrophic Lateral Sclerosis cover

An Overview of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content: * Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6385?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Pridopidine in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.26429?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * What Is Amyotrophic Lateral Sclerosis? [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.19305?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * CNM-Au8 in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.27643?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.0230?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Traumatic Brain Injury and Risk of Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.35119?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

11. mai 2026 - 17 min
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Liker at det er både Podcaster (godt utvalg) og lydbøker i samme app, pluss at man kan holde Podcaster og lydbøker atskilt i biblioteket.
Bra app. Oversiktlig og ryddig. MYE bra innhold⭐️⭐️⭐️

Velg abonnementet ditt

Mest populær

Premium

20 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

Prøv gratis i 14 dager
Deretter 99 kr / måned

Prøv gratis

Premium Plus

100 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

Prøv gratis i 14 dager
Deretter 169 kr / måned

Prøv gratis

Bare på Podimo

Populære lydbøker

Ofte stilte spørsmål

Flere spørsmål og svar
Prøv gratis

Prøv gratis i 14 dager. 99 kr / Måned etter prøveperioden. Avslutt når som helst.